<DOC>
	<DOCNO>NCT00359424</DOCNO>
	<brief_summary>The purpose study compare two different treatment approach recanalization start within 3 hour symptom onset—combined intravenous ( IV ) endovascular therapy standard intravenous ( IV ) rt-PA alone .</brief_summary>
	<brief_title>Interventional Management Stroke ( IMS ) III Trial</brief_title>
	<detailed_description>Stroke remain major cause death disability . Acute thrombolytic therapy offer potential achieve early recanalization ( reopen block artery ) , save tissue , improve outcome . Currently , intravenous ( IV ) recombinant tissue plasminogen activator ( rt-PA ) approve acute stroke therapy . IV rt-PA effective therapy acute ischemic stroke substantial limitation use alone open block arteries The Interventional Management Stroke ( IMS III ) Trial multi-center study compare two different treatment approach restore blood flow brain . One approach , give clot-dissolving drug rt-PA , already FDA-approved give vein ( IV ) . This treatment compare new approach , give rt-PA low dose first IV arm , blood clot brain artery find , small tube catheter site blood clot ( intra-arterial IA ) see good . Both approach must initiate within three hour stroke onset . The primary goal trial determine individual ischemic stroke treat rt-PA use endovascular therapy approach recanalization start within 3 hour onset likely well outcome individual treat standard IV rt-PA alone . While information device use collect , individual device performance primary outcome . Nine hundred participant moderate severe ischemic stroke enrol 50 center United States , Canada , Australia Europe . Subjects randomize 2:1 ratio receive endovascular therapy IV adjustment clinical site NIHSSS stratum . If enrol Amendment 5 later treatment group receive standard approve therapy dose rt-PA ( 0.9 mg/kg , 90 mg max ) administer intravenously one hour . The consent process randomization take place prior anytime forty minute IV bolus dose . If , 40 minute time point , consent obtain randomization complete , patient longer eligible IMS III enrollment . After consent , endovascular therapy group undergo immediate angiography . If clot demonstrate , treatment administer . If clot demonstrate , neurointerventionalist choose currently available trial define endovascular therapy approach , choose treatment feel effective attempt reopen block artery . These approach utilize local regulatory , US FDA IMS III Executive Committee approve device intra-arterial infusion investigational rt-PA use standard microcatheter EKOS Micro-Infusion Catheter® ( US ) embolectomy device include Concentric Retriever Device® , Penumbra System ™ , Solitaire™ FR Revascularization Device . All device must use per manufacturer 's instruction use . Endovascular therapy , whether initially Merci® Retriever , EKOS Micro-Infusion Catheter , Penumbra System™ , Solitaire™ , future device , infusion IA rt-PA via standard microcatheter , must start within 5 hour complete within 7 hour symptom onset . The maximum dose IA rt-PA 22mg ( maximum 2 4 mg bolus infusion rate 10 mg/hr ) . Use tandem device ( i.e . EKOS Micro-Infusion Catheter , Merci Retriever® , Penumbra System™ , Solitaire™ ) single case protocol violation . Only standard microcatheter rt-PA infusion therapy may administer follow attempt device . The primary measure benefit trial ability individual stroke live function independently 3 month stroke . This trial also determine compare safety cost effectiveness combine endovascular therapy standard IV rt-PA approach . Duration study participant approximately 12 month .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>Inclusion Criteria Age : 18 82 year ( i.e. , candidate must 18th birthday , 83rd birthday ) Initiation intravenous rtPA within 3 hour onset stroke symptom . Time onset define last time subject witness baseline ( i.e. , subject stroke symptom upon awaken consider onset begin sleep ) An NIHSSS &gt; /= 10 time intravenous rtPA begin NIHSSS &gt; 7 &lt; 10 occlusion see M1 , ICA basilar artery CTA institution baseline CTA image standard care acute stroke patient . Investigator verification subject received/ receive correct IV rtPA dose estimate weight prior randomization Exclusion Criteria History stroke past 3 month Previous intracranial hemorrhage , neoplasm , subarachnoid hemorrhage , arteriovenous malformation Clinical presentation suggest subarachnoid hemorrhage , even initial CT scan normal Hypertension time treatment ; systolic BP &gt; 185 diastolic &gt; 110 mm Hg ) aggressive measure low BP limit need . Presumed septic embolus , suspicion bacterial endocarditis Presumed pericarditis , include pericarditis acute MI Suspicion aortic dissection Recent ( within 30 day ) surgery biopsy parenchymal organ Recent ( within 30 day ) trauma , internal injury ulcerative wound Recent ( within 90 day ) severe head trauma head trauma loss consciousness Any active recent ( within 30 day ) hemorrhage Pts know hereditary acquire hemorrhagic diathesis , coagulation factor deficiency oral anticoagulant therapy require coagulation lab result prior enrollment . Any subject INR &gt; 1.7 institutionally equivalent prothrombin time exclude . Patients without history suspicion coagulopathy require INR prothrombin time lab result available prior enrollment . Females childbearing potential know pregnant and/or lactate positive pregnancy test admission Baseline lab value : glucose &lt; 50 mg/dl &gt; 400 mg/dl , platelet &lt; 100,000 , Hct &lt; 25 Requires hemodialysis peritoneal dialysis , contraindication angiogram whatever reason Received heparin direct thrombin inhibitor ( Angiomax , argatroban , Refludan , Pradaxa ) within 48 hour must normal partial thromboplastin time ( PTT ) eligible History arterial puncture noncompressible site lumbar puncture previous 7 day History seizure onset stroke History preexist neurological psychiatric disease would confound neurological functional evaluation , mRS score baseline must &lt; 2 . This exclude patient live nursing home fully independent activity daily live ( toileting , dress , eat , cook prepare meal , etc . ) Other serious , advanced , terminal illness Any condition investigator feel would pose significant hazard subject Activase ( Alteplase ) therapy initiate Current participation another research drug treatment protocol Informed consent obtain . High density lesion consistent hemorrhage degree baseline image Significant mass effect midline shift baseline image Large ( &gt; 1/3 middle cerebral artery ) region clear hypodensity baseline CT scan . ( ASPECTS &lt; 4 use guideline ) Sulcal effacement and/or loss greywhite differentiation contraindication tx CT evidence intrapararenchymal tumor Baseline CTA without evidence arterial occlusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>acute ischemic stroke</keyword>
	<keyword>rt-PA</keyword>
	<keyword>thrombolytic</keyword>
	<keyword>recombinant tissue plasminogen activator</keyword>
	<keyword>recanalization</keyword>
	<keyword>blood clot</keyword>
	<keyword>stroke</keyword>
	<keyword>clot-dissolving</keyword>
	<keyword>Activase®</keyword>
	<keyword>Actilyse®</keyword>
	<keyword>Concentric Merci® Retriever</keyword>
	<keyword>EKOS® Micro-Infusion catheter ( MicroLysus )</keyword>
	<keyword>The Penumbra System™</keyword>
	<keyword>Standard microcatheter</keyword>
</DOC>